EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Palisade Bio Inc (PALI) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Palisade Bio Inc $0.63, price $1.57, upside -59.9%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US6963894026

PB Palisade Bio Inc logo Thin data Sep 23, 2026

Palisade Bio Inc

PALI · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.6290 · Strongly overvalued (−60%)
!Quality 33/100
!Weak Growth (revenue 5y −0.8 %/yr)
!negative free cash flow
!Trails peers (3/8)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Palisade Bio Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$3,300 $0.5400 Fair Value $0.6290 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.5400 – $3,300 · fair‑value band $0.4165 – $0.7905 · the $1.57 price screens above the $0.6290 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Palisade Bio in your weekly email

Every Wednesday you see whether Palisade Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.

Show more

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Stock analysis

Palisade Bio Inc (PALI) currently trades at $1.57, while our model-based Fair Value estimate is $0.6290, implying the stock looks roughly 149.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.4165 (bear) to $0.7905 (bull), the price of $1.57 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Palisade Bio Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$16.8M in FY2025.

Key figures

Market cap $325M · P/E ratio 13.1 · EPS (TTM) $0.1200 · Return on equity −36.4% · Return on assets (EBIT) −135% · Free cash flow −$10.8M · Net cash $133M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 131% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −60%, PALI screens richer than that median.

Fair Value models

Bear $0.4165 Fair Value $0.6290 Bull $0.7905
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0881 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.3700 $0.5000 $0.7500 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.3700 $0.5000 $0.7500 51

Open the full fair value analysis →

Notify me when PALI reaches fair value

Put PALI on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 33/100

Of which business quality 42 · Market factors (momentum, volatility) 43

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 55
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 11
Calm price path (market factor)
Momentum 48
Price trend over the last 3–12 months (market factor)
52W Momentum 71
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+164.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,176.5% (2018) → −5,228.0% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PALI screens 150% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Palisade Bio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −60% · Below median
Profitability
Return on assets −23% · Below median
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 13.1× · Cheaper than median
P/B 2.51× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Palisade Bio Inc · Fair Value
$0.6290 −150%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Palisade Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/PALI

Frequently asked questions

Is Palisade Bio Inc (PALI) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.6290 versus a price of $1.57, about −60% upside (overvalued).
What is the fair value of PALI?
Our model-based fair value for Palisade Bio Inc is $0.6290 (as of Sep 23, 2026), built from audited fundamentals. The current price: $1.57.
What is the quality score of PALI?
Palisade Bio Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Palisade Bio Inc (PALI)?
Our model-based price target is the fair value of $0.6290 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.4165, optimistic scenario $0.7905. It is a calculation from audited fundamentals, not an analyst target.
What is the Palisade Bio Inc stock forecast for 2026?
Our models put fair value at $0.6290, about −60% upside versus a price of $1.57 (overvalued). Cautious scenario $0.4165, optimistic scenario $0.7905. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Palisade Bio Inc (PALI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Palisade Bio Inc it is $0.6290 per share (as of Sep 23, 2026), against a price of $1.57. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Palisade Bio Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PALI trades above its calculated fair value: price $1.57, fair value $0.6290, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PALI?
No. The price is what the market pays today ($1.57); the fair value is what the company's own numbers justify ($0.6290). For Palisade Bio Inc the two are $0.9410 per share apart. That gap is exactly why we show both numbers side by side.
How much is Palisade Bio Inc worth?
The market values Palisade Bio Inc at about $325M (market capitalisation, as of Sep 23, 2026). Per share that is $1.57; our models calculate a fair value of $0.6290 per share.
What do the bullish and bearish scenarios say about PALI?
Our models span a range for Palisade Bio Inc: cautious scenario $0.4165, base $0.6290, optimistic $0.7905 per share (as of Sep 23, 2026, price $1.57). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PALI?
Palisade Bio Inc trades at a price-to-earnings ratio of 13.1 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.6290 is built from several models across several years. Other multiples: P/B 2.5.
How solid is the balance sheet of Palisade Bio Inc (PALI)?
Balance-sheet figures for Palisade Bio Inc (as of Sep 23, 2026): return on equity −36.4%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is PALI from its 52-week high?
Palisade Bio Inc trades at $1.57, about 44% below its 52-week high of $2.80 and 131% above the low of $0.6800 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6290 is for.
Which stocks are comparable to Palisade Bio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Palisade Bio Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $1.57, calculated fair value $0.6290 (−60%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PALI calculated?
We run Palisade Bio Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6290, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Palisade Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Palisade Bio Inc (PALI)?
The closing price on Sep 24, 2026 was $1.57. Our model-based fair value is $0.6290, about −60% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Palisade Bio Inc right now?
The price sits above even our optimistic bull case ($0.7905). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.4165 to $0.7905) leaves room in how you read the outcome.

Key figures of Palisade Bio Inc

How large is the market capitalisation of Palisade Bio Inc (PALI)?
The market capitalisation of Palisade Bio Inc is $325M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Palisade Bio Inc (PALI)?
Earnings per share at Palisade Bio Inc are $0.1200 (price ÷ EPS = P/E 13.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Palisade Bio Inc (PALI)?
The return on equity (ROE) of Palisade Bio Inc is −36.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Palisade Bio Inc (PALI)?
On an EBIT basis the return on assets of Palisade Bio Inc is −135% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Palisade Bio Inc (PALI) generate?
The free cash flow of Palisade Bio Inc is −$10.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Palisade Bio Inc (PALI) hold?
Palisade Bio Inc holds more cash than debt, $133M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Palisade Bio Inc in the live analysis

One click puts Palisade Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.